Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?

Authors :: Andersen, Emilie S.
Lund, A.
Bagger, J. I.
Andreasen, C
Grøndahl, MF
Deacon, Carolyn F.
Hartmann, Bolette
Holst, Jens Juul
Knop, Filip Krag
Lauritsen, Tina Vilsbøll
Andersen, Emilie S.
Lund, A.
Bagger, J. I.
Andreasen, C
Grøndahl, MF
Deacon, Carolyn F.
Hartmann, Bolette
Holst, Jens Juul
Knop, Filip Krag
Lauritsen, Tina Vilsbøll
Source :: Andersen , E S , Lund , A , Bagger , J I , Andreasen , C , Grøndahl , MF , Deacon , C F , Hartmann , B , Holst , J J , Knop , F K & Lauritsen , T V 2018 , ' Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes? ' , Diabetes, Obesity and Metabolism , vol. 20 , no. 8 , pp. 1937-1943 .
Publication Year :: 2018

Database :: OAIster
Journal :: Andersen , E S , Lund , A , Bagger , J I , Andreasen , C , Grøndahl , MF , Deacon , C F , Hartmann , B , Holst , J J , Knop , F K & Lauritsen , T V 2018 , ' Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes? ' , Diabetes, Obesity and Metabolism , vol. 20 , no. 8 , pp. 1937-1943 .
Notes :: English
Publication Type :: Electronic Resource
Accession number :: edsoai.on1322710360
Document Type :: Electronic Resource

Tools